Get the Stockscreener App
11.18
0.81%
0.09
Fibrogen Inc stock is traded at $11.18, with a volume of 33,373.
It is up +0.81% in the last 24 hours and up +45.01% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$11.09
Open:
$11.23
24h Volume:
33,373
Relative Volume:
0.63
Market Cap:
$45.21M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
-3.8157
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
+17.75%
1M Performance:
+45.01%
6M Performance:
-36.65%
1Y Performance:
+15.82%
1-Day Range:
$10.79
$11.37
1-Week Range:
$9.6254
$11.71
52-Week Range:
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
11.18 | 45.70M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
RSI Reset May Fuel Rebound in FibroGen Inc.July 2025 Movers & Accurate Intraday Trade Tips - thegnnews.com
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca - MSN
China State Administration for Market Regulation approves sale of FibroGen China to AstraZeneca - MSN
China approves FibroGen’s sale to AstraZeneca, closing expected in Q3 By Investing.com - Investing.com South Africa
AstraZeneca Receives Chinese Approval to Acquire FibroGen China - MarketScreener
FibroGen Gains Approval for Subsidiary Sale to AstraZeneca - MSN
Astrazeneca's Anemia Expansion Strategy Drives $240M Trading Volume Drop to 403rd in Market Activity as $160M FibroGen China Acquisition Nears Closure - AInvest
Fibrogen's 22.7% Surge: Regulatory Green Light Ignites Biotech Bull Run - AInvest
FibroGen announces approval of sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - MarketScreener
FibroGen Announces Approval for Sale of FibroGen China to AstraZeneca. - AInvest
China approves FibroGen’s sale to AstraZeneca, closing expected in Q3 - Investing.com
FibroGen announces approval for FibroGen China sale to AstraZeneca - TipRanks
FibroGen Says China Unit Sale to AstraZeneca Receives Regulatory Approval - MarketScreener
FibroGen Receives Chinese Regulator's Approval for Sale of Subsidiary to AstraZeneca - MarketScreener
FibroGen, Inc. Announces Approval for Sale of FibroGen China to AstraZeneca, On Track for 3Q 2025 Closing - Quiver Quantitative
FibroGen Announces Approval of Sale of FibroGen China to - GlobeNewswire
Major Regulatory Win: FibroGen's $815M China Business Sale to AstraZeneca Gets Green Light from Regulators - Stock Titan
What is FibroGen Inc. s 5 year growth outlookMarket Trend Review & Fast Gain Swing Alerts - classian.co.kr
Can machine learning forecast FibroGen Inc. recoveryWeekly Gains Report & Risk Adjusted Buy/Sell Alerts - Newser
FibroGen Inc. stock chart pattern explainedQuarterly Trade Report & Reliable Momentum Entry Alerts - Newser
FibroGen (NASDAQ:FGEN) Downgraded by Wall Street Zen to Sell - Defense World
HC Wainwright Issues Negative Estimate for FibroGen Earnings - Defense World
FibroGen, IncCommon Stock (Nasdaq:FGEN) Stock Quote - FinancialContent
Will Volume Confirm Reversal in FibroGen Inc.July 2025 Movers & Technical Confirmation Alerts - kangso.co.kr
FibroGen Inc. Charts Flash Early Recovery SignalsEarnings Recap Summary & Weekly Breakout Stock Alerts - newsyoung.net
FibroGen Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
FibroGen Inc.’s volatility index tracking explained2025 Volatility Report & Community Shared Stock Ideas - Newser
FibroGen, Inc. (NASDAQ:FGEN) Q2 2025 Earnings Call Transcript - Insider Monkey
FibroGen’s Strategic Moves and Financial Outlook - The Globe and Mail
Fibrogen, Inc. shares fall 2.05% after-hours following a $7.6 million loss in Q2 2025 earnings. - AInvest
Is FibroGen Inc. forming a bottoming baseFree Profit Target Stock Opportunity Monitor - Newser
Fibrogen's 18.5% Surge: A Biotech Cinderella Story Unfolds? - AInvest
FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances - MSN
FibroGen's Robust Finances and Promising Pipeline Earn Analyst's Buy Rating - AInvest
FibroGen Inc. Reports Q2 2025 Earnings: Strategic Moves, Cost Reductions, and Positive Clinical Updates - AInvest
FibroGen’s Strong Financial Position and Promising Clinical Pipeline Drive Buy Rating - TipRanks
FibroGen: Q2 Earnings Snapshot - New Haven Register
Fibrogen 2025 Q2 Earnings Record Net Income and Strong Revenue Growth - AInvest
Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD) - The Globe and Mail
FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... - Yahoo Finance
FibroGen's Strategic Pivot: China Exit and FG-3246's Oncology Promise Fuel Undervalued Biotech Opportunity - AInvest
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FibroGen Inc (FGEN) Q2 2025 Earnings Call Highlights: Strategic Moves and Cost Reductions ... By GuruFocus - Investing.com Canada
FibroGen's 2025 Q2: Unraveling Key Contradictions in Roxadustat and FG-3246 Clinical Trial Strategies - AInvest
FibroGen's Q2 2025 Earnings Miss: A Catalyst for Long-Term Value or a Warning Signal? - AInvest
Transcript : FibroGen, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Why FibroGen Inc. stock attracts strong analyst attentionValue Holding Return Summary With Outlook - Newser
FibroGen Q2 2025 slides: China sale extends runway amid clinical progress - Investing.com Canada
FibroGen Q2 2025 slides: China sale extends runway amid clinical progress By Investing.com - Investing.com South Africa
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
FibroGen's Strategic Turnaround and Financial Resilience: A Path to Value Recovery? - AInvest
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):